1403864-10-7

Basic information

• Product Name: 5-amino-tetrahydro-2H-pyran-3-ol
• Synonyms: 5-amino-tetrahydro-2H-pyran-3-ol
• CAS NO: 1403864-10-7
• Molecular Weight: 117.148
• Mol File: 1403864-10-7.mol

Chemical Properties

• CAS DataBase Reference: 5-amino-tetrahydro-2H-pyran-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-tetrahydro-2H-pyran-3-ol(1403864-10-7)
• EPA Substance Registry System: 5-amino-tetrahydro-2H-pyran-3-ol(1403864-10-7)

Safety Data

• Hazardous Substances Data: 1403864-10-7(Hazardous Substances Data)

Upstream product

• 1422772-83-5 tert-butyl 5-hydroxy-tetrahydro-2H-pyran-3-ylcarbamate 
• 61363-56-2 2H-pyran-3,5(4H,6H)-dione 
• 265321-06-0 5-amino-2H-pyran-3(6H)-one 
• 688785-30-0 5-ethoxy-2H-pyran-3(6H)-one 
• 1403864-09-4 benzyl N-(5-hydroxyoxan-3-yl)carbamate 
• 98166-23-5 2H-pyran-3(6H)-one 
• 445378-38-1 3,6-dihydro-2H-pyran-3-ol 
• 329684-87-9 (±)-6-[(tert-butyldimethylsilyl)oxy]-3,6-dihydro-2H-pyran-3-one 
• 35436-57-8 6-hydroxy-3,6-dihydro-2H-pyran-3-one 
• 884306-77-8 (5-oxo-tetrahydro-pyran-3-yl)-carbamic acid benzyl ester 
• 98-00-0 (2-furyl)methyl alcohol 

Downstream Products

• 1403864-09-4 benzyl N-(5-hydroxyoxan-3-yl)carbamate 

Relevant articles and documents

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

Pyrimidine amine compound, and preparation method and application thereof

The invention discloses a polycyclic compound, and a preparation method and an application thereof. The invention provides the polycyclic compound represented by formula I, or a pharmaceutically acceptable salt thereof. The compound has a relatively good inhibition effect on CDK7.

Preparing method of 3-amino-5-hydroxyl-tetrahydropyrane and salts thereof

The invention discloses a preparing method and application of 3-amino-5-hydroxyl-tetrahydropyrane and salts thereof. The method includes the following steps of conducting an amination reaction with 2H-pyrane-3,5(4H,6H)-diketone (compound II) as the raw material to obtain a compound III, protecting amino in the structure of the compound III with t-butyloxycarboryl to obtain a compound IV, conducting two-step reaction on the compound IV to obtain a compound V and a compound VI, removing a t-butyloxycarboryl protection group, and conducting salifying to obtain 3-amino-5-hydroxyl-tetrahydropyraneand salts thereof.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors

We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies. Ultimately, our mouse model revealed unexpected toxicity that precluded us from further advancing this series.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.